Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
The purpose of this work was to test the immunogenicity in C57BL mice of two synthetic peptides derived from the constant region of 3D7 and FC27 Plasmodium falciparum MSP2 dimorphic proteins, either microencapsulated into poly-lactide-co-glycolide acid microparticles (PLGA MP) or delivered with the human compatible adjuvant Montanide ISA 720 for comparison. Potent and prolonged antibody responses were obtained for both peptides by using PLGA MP formulations after subcutaneous or intradermal injections. As compared to the subcutaneous route of immunization, the intradermal route induced greater immune responses. Montanide adjuvant was effective in eliciting antibodies against the 3D7 peptide but not against the FC27 peptide. Peptide-specific cytophilic antibodies (IgG2a) were detected after boosting with homologous peptide for all vaccine formulations. MP formulations elicited a lower IgE secretion as compared to that observed for both Montanide formulated vaccines. Our results demonstrate the ability of the polymer microparticles to overcome the lack of immunogenicity of FC27 MSP2 peptide in C57BL mice and their potential to induce desirable immune responses against malaria.
Mata
E
E
Pharmacy and Pharmaceutical Technology Laboratory, Pharmacy Faculty, University of the Basque Country (UPV-EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Carcaboso
A M
AM
Hernández
R M
RM
Igartua
M
M
Corradin
G
G
Pedraz
J L
JL
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000595:Amino Acid Sequence; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000276:immunology*; D003429:Cross Reactions; D005260:Female; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification; D019344:Lactic Acid / Q000008:administration & dosage*; D017780:Malaria Vaccines / Q000008:administration & dosage* / Q000276:immunology; D008353:Mannitol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D051379:Mice; D008810:Mice, Inbred C57BL; D008863:Microspheres; D008969:Molecular Sequence Data; D009829:Oleic Acids / Q000008:administration & dosage*; D010446:Peptide Fragments / Q000276:immunology*; D010963:Plasmodium falciparum / Q000276:immunology*; D011100:Polyglycolic Acid / Q000008:administration & dosage*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage*; D015800:Protozoan Proteins / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D009829:Oleic Acids; D010446:Peptide Fragments; D011108:Polymers; D015800:Protozoan Proteins; D014614:Vaccines, Synthetic; C065974:merozoite surface protein 2, Plasmodium; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C001681:mannide monooleate; D011100:Polyglycolic Acid; D019344:Lactic Acid; D008353:Mannitol